The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
July 8, 2024
View Complete Issue         Table of Contents 2019 
Tarlatamab (Imdelltra) for Small Cell Lung Cancer (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Tarlatamab (Imdelltra) for Small Cell Lung Cancer (online only)
July 8, 2024 (Issue: 1706)
Tarlatamab-dlle (Imdelltra – Amgen), a first-in-class bispecific delta-like ligand 3 (DLL3)-directed CD3 T-cell engager, has received accelerated approval from the FDA for treatment of extensive-stage small cell lung cancer (SCLC) in adults who...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Tarlatamab (Imdelltra) for Small Cell Lung Cancer (online only)
Article code: 1706c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.